Clinical Chemistry Laboratory, University of Milano-Bicocca, Azienda Socio Sanitaria Territoriale di Monza ASST-Monza, San Gerardo Hospital, via Pergolesi 33, 20900, Monza (MB), Italy.
Department of Laboratory Medicine, University of Milano-Bicocca, Azienda Socio Sanitaria Territoriale Brianza ASST-Brianza, Desio Hospital, via Mazzini 1, 20833, Desio (MB), Italy.
J Mycol Med. 2022 Aug;32(3):101278. doi: 10.1016/j.mycmed.2022.101278. Epub 2022 Apr 19.
Vulvovaginal candidiasis (VVC) is the second most common infection of the genital tract affecting millions of women worldwide. Data concerning the distribution and antifungal resistance of Candida species responsible of VVC vary among countries and population studied.
The aim of this work was to determine the prevalence, species distribution and antifungal susceptibility patterns of Candida species among symptomatic women over a 20-year period.
A total of 5,820 unique samples were retrospectively identified. Out of them, 1,046 (18%) were diagnosed with VVC.
Women between 18 and 30 years had the highest prevalence rate of VVC (21%). Women aged less than 18 years and greater than 51 years had the highest prevalence rates of vaginal bacterial infections. Thirty-five (3.3%) women presented recurrent VVC. The most common yeast isolated was C. albicans, followed by C. glabrata, C. krusei, and C. parapsilosis. Non-Candida albicans species (NAC) were more significantly isolated among women aged 51 or above, than in women included in other groups (p < 0.01). Resistance to fluconazole and amphotericin B was infrequent in C. albicans strains. Resistance to fluconazole and amphotericin B was infrequent in C. albicans strains. NAC species presented higher resistance rates against fluconazole (30%) and voriconazole (25%). C. krusei and C. glabrata isolates showed lower MICs than most of the strains against amphotericin B (1 mg/L) and flucytosine (1 mg/L).
Our findings indicated that continued surveillance on Candida species distribution and non-susceptibility rates to antifungals should be routinely reported to help the selection of the most appropriate drug, to avoid the emergence of resistant strains, and to improve the patient's outcomes.
外阴阴道念珠菌病(VVC)是全球影响数百万女性的第二大常见生殖道感染。有关引起 VVC 的念珠菌物种的分布和抗真菌耐药性的数据因国家和研究人群而异。
本研究旨在确定 20 年来,有症状女性中念珠菌物种的流行率、种属分布和抗真菌药敏模式。
共回顾性鉴定了 5820 个独特的样本。其中 1046 个(18%)被诊断为 VVC。
18-30 岁的女性 VVC 患病率最高(21%)。18 岁以下和 51 岁以上的女性阴道细菌感染患病率最高。35 例(3.3%)患者出现复发性 VVC。最常见的分离酵母是白色念珠菌,其次是光滑念珠菌、克柔念珠菌和近平滑念珠菌。非白色念珠菌(NAC)在 51 岁或以上的女性中比其他组的女性更明显分离(p<0.01)。白色念珠菌对氟康唑和两性霉素 B 的耐药性不常见。NAC 对氟康唑(30%)和伏立康唑(25%)的耐药率较高。与大多数菌株相比,克柔念珠菌和光滑念珠菌的分离株对两性霉素 B(1mg/L)和氟胞嘧啶(1mg/L)的 MICs 较低。
我们的研究结果表明,应常规报告对念珠菌种属分布和对抗真菌药物的非敏感性率的持续监测,以帮助选择最合适的药物,避免耐药菌株的出现,并改善患者的预后。